Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D004417: Dyspnea

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (16)


Name (Synonyms) Correlation
drug1785 Knowledge, Attitude, Practice, Awareness, Preference Wiki 0.33
drug3260 Standard-of-care Wiki 0.33
drug1188 Endoscopic intervention Wiki 0.33
Name (Synonyms) Correlation
drug1518 Hydrogen Oxygen Generator with Nebulizer Wiki 0.33
drug2218 No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups Wiki 0.33
drug1018 Delayed diagnostics Anyplex TMII RV16 Detection Wiki 0.33
drug182 AdimrSC-2f Wiki 0.33
drug2170 Nebulized administration of RLF-100 or Placebo Wiki 0.33
drug2809 Rapid diagnostics using Anyplex TMII RV16 Detection Wiki 0.33
drug2776 RLF-100 (aviptadil) Wiki 0.24
drug995 Data Collection Wiki 0.24
drug2767 RECOP unit patient Wiki 0.24
drug2200 Nitric Oxide Wiki 0.17
drug304 Ascorbic Acid Wiki 0.17
drug908 Convalescent plasma Wiki 0.07
drug2505 Placebo Wiki 0.02

Correlated MeSH Terms (14)


Name (Synonyms) Correlation
D005335 Fever of Unknown Origin NIH 0.33
D002637 Chest Pain NIH 0.33
D063806 Myalgia NIH 0.33
Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.13
D004630 Emergencies NIH 0.06
D012127 Respiratory Distress Syndrome, Newborn NIH 0.06
D055371 Acute Lung Injury NIH 0.06
D012128 Respiratory Distress Syndrome, Adult NIH 0.05
D011024 Pneumonia, Viral NIH 0.04
D007239 Infection NIH 0.03
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D003141 Communicable Diseases NIH 0.03
D018352 Coronavirus Infections NIH 0.02
D011014 Pneumonia NIH 0.02

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0002098 Respiratory distress HPO 0.94
HP:0003326 Myalgia HPO 0.33
HP:0100749 Chest pain HPO 0.33
Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.02

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials


1 The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial

Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.

NCT02538770
Conditions
  1. Respiratory Virus Infection
  2. Fever of Unknown Origin
  3. Dyspnea
  4. Chest Pain
Interventions
  1. Other: Rapid diagnostics using Anyplex TMII RV16 Detection
  2. Other: Delayed diagnostics Anyplex TMII RV16 Detection
MeSH:Dyspnea Chest Pain Fever of Unknown Origin
HPO:Chest pain Dyspnea Respiratory distress

Primary Outcomes

Description: The number of days in hospital within one month after randomization

Measure: Duration of hospitalization

Time: One month

Description: Number of days on antimicrobials within one month after randomization

Measure: Antimicrobial consumption

Time: One month

Description: Defined daily doses of antimicrobial agents within one month after randomization

Measure: Antimicrobial consumption

Time: One month

Secondary Outcomes

Measure: Number of radiological examinations

Time: One month

Measure: Cost of other examinations in hospital

Time: One month
2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

NCT04290858
Conditions
  1. Coronavirus Infections
  2. Pneumonia, Viral
  3. Dyspnea
Interventions
  1. Drug: Nitric Oxide
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress

Primary Outcomes

Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

Measure: Reduction in the incidence of intubation and mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Mortality from all causes

Measure: Mortality

Time: 28 days

Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab

Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

Time: 7 days

Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).

Measure: Time to clinical recovery

Time: 28 days
3 Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19

Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or mechanical ventilation. Mortality rates as high as 80% have been reported among those who require mechanical ventilation, despite best available intensive care. Patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 (aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer. The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.

NCT04360096
Conditions
  1. SARS-CoV 2
  2. COVID
  3. ARDS
  4. ALI
  5. Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
  6. Dyspnea
Interventions
  1. Drug: RLF-100 (aviptadil)
  2. Drug: Placebo
  3. Device: Nebulized administration of RLF-100 or Placebo
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: Progression to ARDS is defined as the need for mechanical ventilation

Measure: Progression to ARDS

Time: 28 days

Secondary Outcomes

Description: Blood PO2 as measured by pulse oximetry

Measure: Blood oxygenation

Time: 28 days

Description: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity

Measure: RDP Dsypnea Scale

Time: 28 days

Description: Distance walked in six minutes

Measure: Distance walked in six minutes

Time: 28 days
4 Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial

This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.

NCT04378712
Conditions
  1. Covid-19
  2. Hydrogen/Oxygen Mixed Gas
  3. Dyspnea
Interventions
  1. Device: Hydrogen Oxygen Generator with Nebulizer
  2. Other: Standard-of-care
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The proportion of patients with improved disease severity (by at least one scale) at day 2

Measure: The proportion of patients with improved disease severity at day 2

Time: from baseline to day 2

Description: The proportion of patients with improved disease severity (by at least one scale) at day 3

Measure: The proportion of patients with improved disease severity at day 3

Time: from baseline to day 3

Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge

Measure: The proportion of patients with improved disease severity at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Secondary Outcomes

Description: The change from baseline in oxygen saturation at day 2.

Measure: The change from baseline in oxygen saturation at day 2.

Time: from baseline to day 2

Description: The change from baseline in oxygen saturation at day 3.

Measure: The change from baseline in oxygen saturation at day 3.

Time: from baseline to day 3

Description: The change from baseline in oxygen saturation at the day before hospital discharge.

Measure: The change from baseline in oxygen saturation at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in dyspnea scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in dyspnea scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in dyspnea scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2

Measure: The change from baseline in cough scale at day 2

Time: from baseline to day 2

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3

Measure: The change from baseline in cough scale at day 3

Time: from baseline to day 3

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge

Measure: The change from baseline in cough scale at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in chest pain scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in chest pain scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in chest pain scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in chest distress scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in chest distress scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in chest distress scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)
5 An International Observational Study of Outpatients With SARS-CoV-2 Infection

The general aim of this study is to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations, special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-Cov-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

NCT04385251
Conditions
  1. COVID
  2. COVID19
  3. SARS-CoV 2
  4. Dyspnea
Interventions
  1. Other: Data Collection
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.

Measure: Time to Hospitalization

Time: 28 days

Description: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.

Measure: Time to Expiration

Time: 28 days

Secondary Outcomes

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.

Measure: Rate of Death at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.

Measure: Rate of Death at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.

Measure: Rate of Death at 28 Days

Time: 28 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.

Measure: Rate of Hospitalization at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.

Measure: Rate of Hospitalization at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.

Measure: Rate of Hospitalization at 28 Days

Time: 28 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.

Measure: Participant Health at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.

Measure: Participant Health at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.

Measure: Participant Health at 28 Days

Time: 28 days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 7 Days

Time: 7 Days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 14 Days

Time: 14 Days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 28 Days

Time: 28 Days
6 Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea

This research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out. A central issue of this diagnostic strategy will be to be rapid, since the diagnosis will have to be made in the context of significant flows, with a need to quickly refer patients to the most suitable downstream service, while limiting the risk contamination of caregivers and vulnerable patients if a COVID-19 + patient is admitted to an unsuitable service. However, virological tests do not currently allow rapid results for COVID-19. Research project of investigatory aims to develop a predictive model of the risk of being COVID-19 positive for patients admitted to the emergency room for acute dyspnea.

NCT04422587
Conditions
  1. Emergencies
Interventions
  1. Other: RECOP unit patient
MeSH:Dyspnea Emergencies
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: demographic variables, usual history and treatments, episode characteristics (symptomatology, evolution, treatment taken) and data from the initial clinical examination will be collected by doctor

Measure: Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea

Time: inclusion day

Secondary Outcomes

Description: The COVID-19 virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking

Measure: Describe the characteristics of patients admitted to reCOP units according to their virological status

Time: 30 days

Description: Virological status will be collected by a phone call at the patient

Measure: Virological status

Time: 30 days

Description: Mortality status will be collected by a phone call at the patient

Measure: Mortality status

Time: 30 days
7 Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study

Coronavirus disease 2019 (abbreviated "COVID- 19") is a pandemic respiratory disease that is caused by a novel coronavirus and was first detected in December 2019 in Wuhan, China. The disease is highly infectious, and its main clinical symptoms include fever, dry cough, fatigue, myalgia, and dyspnoea.1 In China, 18.5% of the patients with COVID-19 developed to the severe stage, which is characterized by acute respiratory distress syndrome, septic shock, difficult-to-tackle metabolic acidosis, and bleeding and coagulation dysfunction. After China, COVID-19 spread across the world and many governments implemented unprecedented measures like suspension of public transportation, the closing of public spaces, close management of communities, and isolation and care for infected people and suspected cases. The Malaysian government had enforced Movement Control Order (MCO) from 18th March to 4th May 2020 and henceforth Conditional Movement Control Order (CMCO) until 9th June 2020. The battle against COVID-19 is still continuing in Malaysia and all over the world. Due to the CMO and CMCO in the country, public and private universities have activated the e-learning mode for classes and as the government ordered, universities are closed and no face-to-face activities allowed. This has forced students of all disciplines including dentistry to stay at home which are wide-spread across Malaysia and shift to e- learning mode. To guarantee the final success for fight against COVID-19, regardless of their education status, students' adherence to these control measures are essential, which is largely affected by their knowledge, attitudes, and practices (KAP) towards COVID-19 in accordance with KAP theory. Once the restrictions are eased students have to come back and resume their clinical work in the campus. Hence, in this study we assessed the Knowledge, Attitude, and Practice (KAP) towards COVID-19 and the students preference for online learning.

NCT04449081
Conditions
  1. Acute Respiratory Distress Syndrome
  2. Corona Virus Infection
  3. Acute Lung Injury
  4. Fever
  5. Myalgia
  6. Cough
  7. Dyspnea
  8. Septic Shock
  9. Bleeding
Interventions
  1. Behavioral: Knowledge, Attitude, Practice, Awareness, Preference
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myalgia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lun Acute Lung Injury Dyspnea Lung Injury
HPO:Dyspnea Myalgia Respiratory distress

Primary Outcomes

Description: KAP towards COVID-19 was assessed using validated questionnnaire

Measure: Knowledge, Attitude, Practice of dental students towards COVID-19

Time: 4 months

Secondary Outcomes

Description: Awareness level about Infection control to prevent COVID-19 transmission in clinics was assesed using a standardized questionnaire

Measure: Awareness level about Infection control to prevent COVID-19 transmission in clinics

Time: 4 months

Description: Preference towards online learning. was assessed using a standard questionnaire

Measure: Preference towards online learning.

Time: 4 months
8 Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study

The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.

NCT04505631
Conditions
  1. Covid19
  2. Dyspnea
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry

Measure: Presence of respiratory sequelae

Time: 6 months after hospital discharge

Secondary Outcomes

Measure: Presence of respiratory sequelae on low dose thoracic tomodensitometry

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced vital capacity (FVC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced vital capacity (FVC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced expiratory volume in 1 second (FEV1, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced expiratory volume in 1 second (FEV1, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Total lung capacity (TLC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Total lung capacity (TLC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Residual volume (RV, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Residual volume (RV, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: RV/TLC ratio (%)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: RV/TLC ratio (%)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal inspiratory pressure (MIP, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal inspiratory pressure (MIP, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal expiratory pressure (MEP, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal expiratory pressure (MEP, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: pH

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: pH

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen partial pressure (PaO2, mmHg)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen partial pressure (PaO2, mmHg)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Bicarbonate concentration (mmol/L)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Bicarbonate concentration (mmol/L)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen saturation (SaO2, %)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen saturation (SaO2, %)

Time: 3 months after hospital discharge

Description: Six-minute walk test will be performed under ambient air and under oxygen

Measure: Six-minute walk test

Time: 6 months after hospital discharge

Description: Six-minute walk test will be performed under ambient air and under oxygen

Measure: Six-minute walk test

Time: 3 months after hospital discharge
9 Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon

Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom. The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table. The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4). The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.

NCT04522037
Conditions
  1. Patients Hospitalized in the Hospices Civils of Lyon
  2. COVID-19 Disease
  3. Moderate to Severe Dyspnea
  4. Without Resuscitation Objective Management
Interventions
  1. Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The respiratory rate is analyzed at Hour 0 and Hour 12 by a scope.

Measure: Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment

Time: Hour 0 and Hour 12 after initiation of morphinic treatment

HPO Nodes


HP:0002094: Dyspnea
Genes 466
RSPH1 PFN1 NKX2-1 SPAG1 ATRX PRRX1 TSC2 RPS28 SH2B3 STAT5B LGI4 DNAH1 UBE3B PON1 DPM2 PRKAR1A COL2A1 GATA6 SFTPC RRM2B PPARGC1A DNAAF1 TRAK1 LTBP3 MAPT DNAH9 FAM13A STN1 ORC6 TRPM4 HCCS RUNX2 GLA DBH DNA2 TERT RSPH4A CCR6 TNNT2 GAS8 AK9 MEGF10 SLC5A7 ACVRL1 COLQ FGFR1 HLA-B CCDC65 RUNX1 BCOR ORC6 SERPINA1 MYH11 SCO2 NDUFS2 NEK1 SETBP1 IRF2BP2 ALAS2 MYBPC3 SCN4A VPS33A GNAS OPTN COL13A1 GBA OTX2 C9ORF72 SCNN1A UNC13A CSF2RB CHRNE ACADVL COX8A SFTPC ABCG8 SFTPB MARS1 NOD2 NUMA1 COL2A1 MAPT LAMB3 FOXF1 COL13A1 ERBB4 SCN5A UBQLN2 GALC DNAAF6 SFTPA2 JPH2 KAT6A CCDC103 SQSTM1 SPP1 SOX9 SSR4 DNAAF4 PLEC FGFR2 TNNI3 NPM1 ATP11A SCNN1B EDN1 ND5 CSPP1 MUC5B NAGS MYH11 CCNF EFEMP2 MYO9A IRF5 FOXJ1 AGRN LDLR WIPF1 COX6B1 MMAA SNAP25 TSC1 CAV1 SRP54 SMAD3 COX14 DCTN1 EP300 DNAL1 NEB TREM2 CAV1 NABP1 PNKD TERC ELN PYGM SFTPC STAT4 HLA-DRB1 WAS FLNC GMNN CASR RSPH9 NEFH COA3 GATA4 SOD1 EFTUD2 TRMT5 ITGA3 MGME1 TNNC1 VCP LAMC2 TARDBP FBN1 TBL1XR1 MRPL3 TGFBR1 MYPN MYL2 CREBBP DSC2 ZFPM2 COL1A2 SLC25A1 ACADM HBB LRP4 IRAK1 SCO2 EPOR SCN1B DNAJB6 DNAI1 DPM1 BMPER DNAJB13 GAA FBP1 ETFDH PARN STX16 CHMP2B FOXP3 CFAP410 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 ND3 CPT2 SLC18A3 CHRND CDC45 NR2F2 TRNW NKX2-1 SCNN1G CDC6 TGFBR2 ND6 SLC52A3 FGFR2 MYLK LRRC6 RPS26 DNAAF5 CCNO NDUFAF3 COX20 CFTR TTN DNA2 USP9X NGLY1 XYLT1 MGME1 CYB5R3 LRRC56 EPHA4 MMUT SYT2 LAMB2 TERT PMM2 DNAAF3 SLC25A4 FLNC STT3B DPP9 CHRNA1 BMPR2 ASAH1 AIFM1 EOMES CRELD1 CYB5R3 JAK2 CBL SCO1 KLHL7 VAMP1 ALDH7A1 MCIDAS PGM1 DAO SCN4A NAGS NDUFB8 TACO1 TRNE LYRM4 PON2 SURF1 COX7B COL2A1 CFAP221 PET100 LAMA3 CHRNB1 PML PIGT RPGR STK36 EDA HNRNPA1 HLCS DSP IFT52 FBLN5 NPPA OFD1 APOB PRKCSH COL2A1 CHRNE NME8 FUS ND1 SIK1 ADNP STT3B GLE1 TGFB2 ADCY6 COX10 CFAP298 SMPD1 MATR3 CFAP300 BTNL2 PON3 SLC25A1 HLA-DRB1 RAPSN SPEF2 AIMP2 ACTA2 SCN5A ZBTB16 ZMYND10 SMAD4 COA8 GNAS PRKG1 COQ7 TRIP11 MUSK GLT8D1 ATP6 CCDC39 ARMC4 ABCA3 TRMU CYB5A PRRX1 IKZF1 GNAI3 DNAI2 ORC1 RARA NEK10 SFTPA1 ZIC3 ANXA11 POLG LIFR SLC2A10 GTPBP3 DMPK DOK7 POLG2 MYL3 RTEL1 PCSK9 TAF15 CSF2RA FGFR2 CHAT KCNJ6 FIP1L1 ISCU ASXL1 SERPING1 ETFA ATXN2 DYNC2LI1 TRNK TRNN FBP1 TBX4 TSC2 CHRNA1 COA8 SBDS SLC12A3 VPS33A SFTPA2 TWNK MMUT COPA PLCB4 STAT5B ETFB ENG TRNS1 GBA GAS2L2 PRKAR1A SCN4A FGFR2 VCP BMPER TET2 CCDC151 MFAP5 TRPV6 TBK1 NUP214 MMAB DNASE1L3 SLC35A1 CLCNKB TK2 LOX RNU4ATAC TET2 FAM20C LDLRAP1 IFT81 CHRNB1 DISC1 TGFB3 ERF FIG4 STAT3 MUC5B CHRNE EPHB4 PRPH DNAH5 GBA PUF60 BTNL2 TTC12 ORC4 TUBB4A ABCG5 ARX CRLF1 SDCCAG8 GYG1 CHCHD10 TBC1D24 ORC1 EIF2AK4 MPC1 CHRND SRSF2 CCDC40 CSF2RB ND4 ANG CHAT TSC1 VAPB NKX2-5 DNAAF3 TTC25 VCL DNAAF2 TRNK DPM2 DRC1 PRRT2 ND2 TRNE IL1RN RSPH3 DNAJC21 KIF20A USP9X HLA-DRB1 TRNV PSAP HYDIN KCNA1 CDT1 CCDC114 MAT2A ABCA3 GATA6 NDUFB11 CNTNAP1 FOXE3 CCN2 GNAS AGRN TRIP11 TET2 DNAH11
Protein Mutations 0
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0002094: Dyspnea
Genes 466
RSPH1 PFN1 NKX2-1 SPAG1 ATRX PRRX1 TSC2 RPS28 SH2B3 STAT5B LGI4 DNAH1 UBE3B PON1 DPM2 PRKAR1A COL2A1 GATA6 SFTPC RRM2B PPARGC1A DNAAF1 TRAK1 LTBP3 MAPT DNAH9 FAM13A STN1 ORC6 TRPM4 HCCS RUNX2 GLA DBH DNA2 TERT RSPH4A CCR6 TNNT2 GAS8 AK9 MEGF10 SLC5A7 ACVRL1 COLQ FGFR1 HLA-B CCDC65 RUNX1 BCOR ORC6 SERPINA1 MYH11 SCO2 NDUFS2 NEK1 SETBP1 IRF2BP2 ALAS2 MYBPC3 SCN4A VPS33A GNAS OPTN COL13A1 GBA OTX2 C9ORF72 SCNN1A UNC13A CSF2RB CHRNE ACADVL COX8A SFTPC ABCG8 SFTPB MARS1 NOD2 NUMA1 COL2A1 MAPT LAMB3 FOXF1 COL13A1 ERBB4 SCN5A UBQLN2 GALC DNAAF6 SFTPA2 JPH2 KAT6A CCDC103 SQSTM1 SPP1 SOX9 SSR4 DNAAF4 PLEC FGFR2 TNNI3 NPM1 ATP11A SCNN1B EDN1 ND5 CSPP1 MUC5B NAGS MYH11 CCNF EFEMP2 MYO9A IRF5 FOXJ1 AGRN LDLR WIPF1 COX6B1 MMAA SNAP25 TSC1 CAV1 SRP54 SMAD3 COX14 DCTN1 EP300 DNAL1 NEB TREM2 CAV1 NABP1 PNKD TERC ELN PYGM SFTPC STAT4 HLA-DRB1 WAS FLNC GMNN CASR RSPH9 NEFH COA3 GATA4 SOD1 EFTUD2 TRMT5 ITGA3 MGME1 TNNC1 VCP LAMC2 TARDBP FBN1 TBL1XR1 MRPL3 TGFBR1 MYPN MYL2 CREBBP DSC2 ZFPM2 COL1A2 SLC25A1 ACADM HBB LRP4 IRAK1 SCO2 EPOR SCN1B DNAJB6 DNAI1 DPM1 BMPER DNAJB13 GAA FBP1 ETFDH PARN STX16 CHMP2B FOXP3 CFAP410 GATA6 SLC25A3 TRNL1 POMT1 ADAMTS13 ND3 CPT2 SLC18A3 CHRND CDC45 NR2F2 TRNW NKX2-1 SCNN1G CDC6 TGFBR2 ND6 SLC52A3 FGFR2 MYLK LRRC6 RPS26 DNAAF5 CCNO NDUFAF3 COX20 CFTR TTN DNA2 USP9X NGLY1 XYLT1 MGME1 CYB5R3 LRRC56 EPHA4 MMUT SYT2 LAMB2 TERT PMM2 DNAAF3 SLC25A4 FLNC STT3B DPP9 CHRNA1 BMPR2 ASAH1 AIFM1 EOMES CRELD1 CYB5R3 JAK2 CBL SCO1 KLHL7 VAMP1 ALDH7A1 MCIDAS PGM1 DAO SCN4A NAGS NDUFB8 TACO1 TRNE LYRM4 PON2 SURF1 COX7B COL2A1 CFAP221 PET100 LAMA3 CHRNB1 PML PIGT RPGR STK36 EDA HNRNPA1 HLCS DSP IFT52 FBLN5 NPPA OFD1 APOB PRKCSH COL2A1 CHRNE NME8 FUS ND1 SIK1 ADNP STT3B GLE1 TGFB2 ADCY6 COX10 CFAP298 SMPD1 MATR3 CFAP300 BTNL2 PON3 SLC25A1 HLA-DRB1 RAPSN SPEF2 AIMP2 ACTA2 SCN5A ZBTB16 ZMYND10 SMAD4 COA8 GNAS PRKG1 COQ7 TRIP11 MUSK GLT8D1 ATP6 CCDC39 ARMC4 ABCA3 TRMU CYB5A PRRX1 IKZF1 GNAI3 DNAI2 ORC1 RARA NEK10 SFTPA1 ZIC3 ANXA11 POLG LIFR SLC2A10 GTPBP3 DMPK DOK7 POLG2 MYL3 RTEL1 PCSK9 TAF15 CSF2RA FGFR2 CHAT KCNJ6 FIP1L1 ISCU ASXL1 SERPING1 ETFA ATXN2 DYNC2LI1 TRNK TRNN FBP1 TBX4 TSC2 CHRNA1 COA8 SBDS SLC12A3 VPS33A SFTPA2 TWNK MMUT COPA PLCB4 STAT5B ETFB ENG TRNS1 GBA GAS2L2 PRKAR1A SCN4A FGFR2 VCP BMPER TET2 CCDC151 MFAP5 TRPV6 TBK1 NUP214 MMAB DNASE1L3 SLC35A1 CLCNKB TK2 LOX RNU4ATAC TET2 FAM20C LDLRAP1 IFT81 CHRNB1 DISC1 TGFB3 ERF FIG4 STAT3 MUC5B CHRNE EPHB4 PRPH DNAH5 GBA PUF60 BTNL2 TTC12 ORC4 TUBB4A ABCG5 ARX CRLF1 SDCCAG8 GYG1 CHCHD10 TBC1D24 ORC1 EIF2AK4 MPC1 CHRND SRSF2 CCDC40 CSF2RB ND4 ANG CHAT TSC1 VAPB NKX2-5 DNAAF3 TTC25 VCL DNAAF2 TRNK DPM2 DRC1 PRRT2 ND2 TRNE IL1RN RSPH3 DNAJC21 KIF20A USP9X HLA-DRB1 TRNV PSAP HYDIN KCNA1 CDT1 CCDC114 MAT2A ABCA3 GATA6 NDUFB11 CNTNAP1 FOXE3 CCN2 GNAS AGRN TRIP11 TET2 DNAH11
Protein Mutations 0
SNP 0

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook